Log in to search using one of your social media accounts:

 

Distal Bicep Tendon Rip Tied to Transthyretin Amyloidosis
Findings in patients with heart failure with preserved ejection fraction (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - September 13, 2017 Category: Respiratory Medicine Tags: Cardiology, Internal Medicine, Orthopedics, Pathology, Pulmonology, Journal, Source Type: news

Faster diagnosis of inherited and lethal nerve disease could advance search for new treatments
(Johns Hopkins Medicine) Johns Hopkins physicians report success in a small study of a modified skin biopsy that hastens the earlier diagnosis of an inherited and progressively fatal nerve disease and seems to offer a clearer view of the disorder's severity and progression. With a quicker and less invasive way to visualize the hallmark protein clumps of the rare but lethal disease -- familial transthyretin amyloidosis -- the researchers say they hope to more rapidly advance clinical trials of treatments that may slow the disease and extend patients' lives. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 11, 2017 Category: International Medicine & Public Health Source Type: news

X-Rays Of The Earliest Stage Of Alzheimer's Offer Critical Clue About How It Starts
This reporting is brought to you by HuffPost’s health and science platform, The Scope. Like us on Facebook and Twitter and tell us your story: scopestories@huffingtonpost.com. Sarah DiGiulio is The Huffington Post’s sleep reporter. -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website. (Source: Healthy Living - The Huffington Post)
Source: Healthy Living - The Huffington Post - March 27, 2017 Category: Consumer Health News Source Type: news

X-Rays Of The Earliest Stage Of Alzheimer's Offer Critical Clue About How It Starts
This reporting is brought to you by HuffPost’s health and science platform, The Scope. Like us on Facebook and Twitter and tell us your story: scopestories@huffingtonpost.com. Sarah DiGiulio is The Huffington Post’s sleep reporter. -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website. (Source: Science - The Huffington Post)
Source: Science - The Huffington Post - March 27, 2017 Category: Science Source Type: news

Discovery's Edge: Cell research on amyloidosis
At Mayo Clinic, Marina Ramirez-Alvarado, Ph.D., studies one type of protein abnormality associated with a complex and incurable disease called light chain amyloidosis. This type of amyloidosis is the most common and can affect the heart, kidneys, skin, nerves, and liver.?Dr. Ramirez-Alvarado and her team just published a paper on their most recent findings in [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 21, 2017 Category: Databases & Libraries Source Type: news

New Options for Treating AL Amyloidosis
New treatment options are now available for light-chain amyloidosis, with additional ones on the way, according to a presentation at the 21st Annual International Congress on Hematologic Malignancies. (Source: CancerNetwork)
Source: CancerNetwork - February 23, 2017 Category: Cancer & Oncology Authors: Mark L. Fuerst Tags: Hematologic Malignancies Conferences/ICHM 2017 News Source Type: news

Circulating RBP4 IDs HF Caused by Transthyretin Amyloidosis (CME/CE)
(MedPage Today) --'Simple blood test'for underrecognized cause of heart failure (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 8, 2017 Category: Cardiology Source Type: news

Engineering team finds compound may halt molecular cause of often-fatal condition
A team of engineers say a compound found in green tea could have lifesaving potential for patients with multiple myeloma and amyloidosis, who face often-fatal medical complications associated with bone-marrow disorders. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 6, 2017 Category: Science Source Type: news

The power of tea
(Washington University in St. Louis) A team of engineers at Washington University in St. Louis and their German collaborators say a compound found in green tea could have lifesaving potential for patients with multiple myeloma and amyloidosis, who face often-fatal medical complications associated with bone-marrow disorders. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 6, 2017 Category: Biology Source Type: news

Amyloidosis Treatments Miss the Heart of the Problem
(MedPage Today) -- Only modest improvement in end organ function (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - December 7, 2016 Category: Urology & Nephrology Source Type: news

With promising results from emerging therapies, research yields hope for amyloidosis
Two new treatments are showing promise and overall survival is on the rise for AL amyloidosis, according to a series of studies. Immunoglobulin light-chain amyloidosis (AL) is a rare, life-threatening disease that occurs when toxic proteins build up in organs, which alters their normal function. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 1, 2016 Category: Science Source Type: news

With promising results from emerging therapies, Penn research yields hope for amyloidosis
(University of Pennsylvania School of Medicine) Two new treatments are showing promise and overall survival is on the rise for AL amyloidosis, according to a series of studies involving researchers in the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 1, 2016 Category: Cancer & Oncology Source Type: news

[Research Article] De novo design of a biologically active amyloid
Most human proteins possess amyloidogenic segments, but only about 30 are associated with amyloid-associated pathologies, and it remains unclear what determines amyloid toxicity. We designed vascin, a synthetic amyloid peptide, based on an amyloidogenic fragment of vascular endothelial growth factor receptor 2 (VEGFR2), a protein that is not associated to amyloidosis. Vascin recapitulates key biophysical and biochemical characteristics of natural amyloids, penetrates cells, and seeds the aggregation of VEGFR2 through direct interaction. We found that amyloid toxicity is observed only in cells that both express VEGFR2 and a...
Source: ScienceNOW - November 10, 2016 Category: Science Authors: Rodrigo Gallardo Source Type: news

JNM: Florbetaben-PET detects cardiac amyloidosis
Australian researchers have shown the proficiency of PET with the radiotracer...Read more on AuntMinnie.comRelated Reading: Piramal Imaging inks Taiwan deal Scintigraphy detects amyloid-related heart condition Florbetaben-PET finds more beta-amyloid plaques Florbetapir shows promise in detecting cardiac amyloid Study shows PiB-PET detects amyloid plaque in heart (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 4, 2016 Category: Radiology Source Type: news

PET imaging visualizes hard-to-diagnose cardiac amyloidosis
(Society of Nuclear Medicine) Researchers at Princess Alexandra Hospital, Brisbane, Australia, have demonstrated that cardiac amyloidosis (abnormal deposits of proteins in the heart), which is notoriously difficult to diagnose, can be visualized noninvasively with positron emission tomography (PET) using the radiotracer fluorine-18 (F-18)-florbetaben. The study is published in the November issue of 'The Journal of Nuclear Medicine.' (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 1, 2016 Category: Global & Universal Source Type: news

Planar Cardiac Imaging Spots Transthyretin Cardiac Amyloidosis Planar Cardiac Imaging Spots Transthyretin Cardiac Amyloidosis
Technetium 99mpyrophosphate (Tc99mPYP) cardiac imaging effectively and noninvasively identifies transthyretin cardiac amyloidosis (ATTR-CA), according to findings from an observational study.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - September 2, 2016 Category: Radiology Tags: Radiology News Source Type: news

DHA May Slow Cognitive Decline
There is a wealth of evidence that omega-3 fats such as DHA, found in salmon and other fish, play a role in both brain and heart health. In fact, infant formulas are supplemented with a type of DHA because it is critical to newborns' brain development. Now, a new study published in JAMA Neurology has shown an association between low levels of DHA and cerebral amyloidosis, a precursor of the beta-amyloid plaques common in the brains of people with Alzheimer's disease. The researchers took blood samples and conducted Amyvid PET scans of the brains of 61 seniors who did not show signs of cognitive impairment. (These scans, ...
Source: Healthy Living - The Huffington Post - August 17, 2016 Category: Consumer Health News Source Type: news

Potential drug candidates could intervene in deadly diseases
Scientists have identified drug candidates that can boost a cell's ability to catch the 'typos' in protein production that can cause a deadly disease called amyloidosis, revealing a new approach to intervene in human disease. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 20, 2016 Category: Science Source Type: news

TSRI team finds potential drug candidates that could intervene in deadly diseases
(Scripps Research Institute) In a new study, scientists at The Scripps Research Institute have identified drug candidates that can boost a cell's ability to catch the 'typos' in protein production that can cause a deadly disease called amyloidosis, revealing a new approach to intervene in human disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 20, 2016 Category: Global & Universal Source Type: news

Bortezomib-Based Chemo Ups AL Cardiac Amyloidosis SurvivalBortezomib-Based Chemo Ups AL Cardiac Amyloidosis Survival
Heart failure due to light-chain amyloidosis is "one of the most devastating diagnoses a cardiologist may give a patient," one expert observes. Heartwire from Medscape (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 29, 2016 Category: Consumer Health News Tags: Cardiology News Source Type: news

Diabetes drugs may be useful for Alzheimer's, mice research finds
Conclusion Both Alzheimer's disease and diabetes seem to have become more common in recent years, causing illness and putting strain on the health service. News that the two illnesses may have a common cause raises hopes that drugs which help with one disease may also be of use in treating another. Trials of a diabetes drug on people with Alzheimer's disease are reported to be underway, although no results have been published yet. This study, suggesting a mechanism which may be involved in the early stages of both diseases, may increase the likelihood that common treatments will be useful. The study's main limitation is th...
Source: NHS News Feed - June 22, 2016 Category: Consumer Health News Tags: Neurology Mental health Diabetes Source Type: news

Calling All Researchers: Submit Your Grant Applications for the 2016 Brian D. Novis Research Awards
The Brian D. Novis Research Awards honor the IMF's founder Brian Novis, who died of multiple myeloma in July of 1992. The awards go to researchers doing work in the field of multiple myeloma and related disorders including smoldering myeloma, MGUS (monoclonal gammopathy of undetermined significance), as well as immunoglobulin-derived amyloidosis. The 2016 awards are $50,000 each for junior grants and $80,000 for senior grants. August 1, 2016 is the deadline for applications. For more information and grant applications, click HERE. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - May 27, 2016 Category: Hematology Source Type: news

Amyloidosis
Title: AmyloidosisCategory: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 5/19/2016 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - May 19, 2016 Category: Rheumatology Source Type: news

Sylvester researchers develop novel disease model to study multiple myeloma
(University of Miami Miller School of Medicine) Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have developed an animal model that allows them to better understand the mechanisms that lead to the development of multiple myeloma, a hematologic cancer of plasma cells, and the amyloidosis that sometimes accompanies it. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 5, 2016 Category: Biology Source Type: news

Protein trigger for juvenile idiopathic arthritis identified
US scientists have successfully identified a protein that plays a potentially key role in triggering juvenile idiopathic arthritis.Scientists at the Albert Einstein College of Medicine in New York have identified a human protein called transthyretin (TTR) that causes an autoimmune reaction in the joints of youngsters with this form of the disease - a discovery that could pave the way for new treatment options.The role of the TTR protein Juvenile idiopathic arthritis is the most common form of childhood arthritis and is understood to be an autoimmune disease, caused by antibodies attacking certain proteins in a person's...
Source: Arthritis Research UK - February 29, 2016 Category: Rheumatology Source Type: news

Leading efforts to better understand amyloidosis diseases
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today. We’re pleased to host a guest blog from Isabelle Lousada, president and CEO of the Amyloidosis Research Consortium. (Source: The Catalyst)
Source: The Catalyst - February 26, 2016 Category: Pharmaceuticals Authors: Guest Contributor Tags: Rare Diseases & Rare Disease Day Source Type: news

Karmanos’ Myeloma and Amyloidosis team receives prestigious award for contributions to multiple myeloma research
(Source: Karmanos Cancer Institute)
Source: Karmanos Cancer Institute - February 19, 2016 Category: Cancer & Oncology Source Type: news

Karmanos ’ Myeloma and Amyloidosis team receives prestigious award for contributions to multiple myeloma research
(Source: Karmanos Cancer Institute)
Source: Karmanos Cancer Institute - February 19, 2016 Category: Cancer & Oncology Source Type: news

Astrocytes implicated in preclinical AD
Astrocytes are activated in the brains of people with autosomal dominant Alzheimer’s disease long before symptoms appear and even before amyloidosis begins, a study shows. (Source: MedWire News)
Source: MedWire News - February 13, 2016 Category: Consumer Health News Tags: Alzheimer ' s disease Source Type: news

Discovery: Molecular mechanism at root of familial amyloidosis and other diseases
A team of local researchers has proposed a molecular mechanism that may be responsible for the development of life-threatening diseases called amyloidoses. (Source: Parkinson's Disease News From Medical News Today)
Source: Parkinson's Disease News From Medical News Today - November 13, 2015 Category: Neurology Tags: Alzheimer's / Dementia Source Type: news

Molecular mechanism at root of familial amyloidosis and other diseases
A team of local researchers has proposed a molecular mechanism that may be responsible for the development of life-threatening diseases called amyloidoses. The best known of such diseases is Alzheimer's disease, but there are many others that are receiving increased scrutiny, in part because of mounting evidence linking them to atherosclerosis and aging. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 12, 2015 Category: Science Source Type: news

Predicting Progressive Atrophy in Mild Cognitive ImpairmentPredicting Progressive Atrophy in Mild Cognitive Impairment
Dr Barclay reviews a study aiming to determine how beta-amyloidosis and neurodegeneration predict regional progression of hypometabolism and atrophy in patients with mild cognitive impairment. Medscape Neurology (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - November 5, 2015 Category: Neurology Tags: Neurology & Neurosurgery Viewpoint Source Type: news

Prothena to Initiate PRONTO, a Global Trial of NEOD001 in Patients With AL Amyloidosis With Primary Endpoint of Cardiac Response
(Source: Medical News (via PRIMEZONE))
Source: Medical News (via PRIMEZONE) - October 15, 2015 Category: Pharmaceuticals Source Type: news

High dose chemo & stem cell transplantation results in long-term survival for amyloid patients
(Boston University Medical Center) Patients with Light-chain amyloidosis who are treated with high-dose chemotherapy and autologous (one's own) stem cell transplantation (HDM/SCT) have the greatest success for long-term survival. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 8, 2015 Category: Cancer & Oncology Source Type: news

Light Chain Amyloidosis No Systemic Threat (CME/CE)
(MedPage Today) -- Thorough initial evaluation, long-term follow-up essential (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 25, 2015 Category: Hematology Source Type: news

A Predictor of Early Cognitive Decline A Predictor of Early Cognitive Decline
A new study looks at the relationship between cerebral amyloidosis and cognitive decline in patients with autosomal dominant Alzheimer disease. Medscape Neurology (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 16, 2015 Category: Neurology Tags: Neurology & Neurosurgery Viewpoint Source Type: news

Brain's Ability to Clear Amyloid Declines With AgeBrain's Ability to Clear Amyloid Declines With Age
The aging brain takes longer to clear amyloid-beta, a new study shows, which may explain why risk for the disease increases with age. It may also in the future allow risk prediction for Alzheimer's and amyloidosis. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 19, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Alnylam begins patisiran’s Apollo-Ole trial for ATTR amyloidosis
Alnylam Pharmaceuticals has started the Phase III open-label extension study (Apollo-Ole) with patisiran, an investigational RNAi therapeutic targeting transthyretin (TTR) to treat TTR-mediated amyloidosis (ATTR amyloidosis) in patients with familial… (Source: Drug Development Technology)
Source: Drug Development Technology - July 20, 2015 Category: Pharmaceuticals Source Type: news

Two-Step Tx Shows Promise in Systemic Amyloidosis (CME/CE)
(MedPage Today) -- Significant declines in liver stiffness with an anti-amyloid monoclonal antibody. (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - July 15, 2015 Category: Gastroenterology Source Type: news

Molecular Heart Imaging Could Spot Cardiac AmyloidosisMolecular Heart Imaging Could Spot Cardiac Amyloidosis
Myocardial scintigraphy with the bone radiotracer technetium-99m hydroxymethylene diphosphonate has prognostic value for patients with transthyretin-type amyloidosis, new research suggests. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 9, 2015 Category: Consumer Health News Tags: Radiology News Source Type: news

Localized Amyloidosis Carries Low Risk of Progression to Systemic DiseaseLocalized Amyloidosis Carries Low Risk of Progression to Systemic Disease
The prognosis for patients with localized amyloidosis appears to be good for long-term survival, but patients still need to be assessed and monitored for the more dangerous systemic amyloidosis, UK researchers report. Reuters Health Information (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - May 26, 2015 Category: Primary Care Tags: Family Medicine/Primary Care News Source Type: news

Calling All Researchers: Submit Your Grant Applications for the 2016 Brian D. Novis Research Awards
The Brian D. Novis Research Awards honor the IMF's founder Brian Novis, who died of multiple myeloma in July of 1992. The awards go to researchers doing work in the field of multiple myeloma and related disorders including smoldering myeloma, MGUS (monoclonal gammopathy of undetermined significance), as well as immunoglobulin derived amyloidosis. The 2016 awards are $50,000 each for junior grants and $80,000 for senior grants. August 3, 2015 is the deadline for applications. For more information and grant applications click HERE. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - April 23, 2015 Category: Hematology Source Type: news

Consumer Information on: Lixelle Beta 2-microglobulin Apheresis Column - H130001
The Lixelle Beta 2-microglobulin Apheresis Column (Lixelle Column) is a device that treats dialysis-related amyloidosis, a complication of kidney failure. The Lixelle Column contains specialized beads that remove a protein called Beta 2-microglobulin... (Source: Food and Drug Adminstration (FDA): CDRHNew)
Source: Food and Drug Adminstration (FDA): CDRHNew - March 19, 2015 Category: Medical Equipment Source Type: news

FDA OKs First Device for Dialysis-Related AmyloidosisFDA OKs First Device for Dialysis-Related Amyloidosis
The authorization had a special humanitarian device exemption, used for a disease or condition that affects fewer than 4000 people in the United States each year. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 11, 2015 Category: Consumer Health News Tags: Nephrology News Alert Source Type: news

UCLA study shows feasibility of blood-based test for diagnosing Alzheimer’s Disease
UCLA researchers have provided the first evidence that a simple blood test could be developed to confirm the presence of beta amyloid proteins in the brain, which is a hallmark of Alzheimer’s disease. Although approximately 5 million Americans are living with Alzheimer’s, no reliable blood-based test currently exists for the neurodegenerative disorder that is the sixth-leading cause of death in the United States. Using blood-based biomarkers — a signature of proteins in the blood that indicate the presence of a disease — to diagnose Alzheimer’s could be a key advance. “Blood-based biomar...
Source: UCLA Newsroom: Health Sciences - March 11, 2015 Category: Universities & Medical Training Source Type: news

FDA Authorizes Use Of First Device To Treat Patients With Dialysis-Related Amyloidosis
The U.S. Food and Drug Administration recently authorized use of Lixelle Beta 2-microglobulin Apheresis Column, the first device to treat dialysis-related amyloidosis (DRA). (Source: Medical Design Online News)
Source: Medical Design Online News - March 10, 2015 Category: Medical Equipment Source Type: news

First Device Approved for Dialysis-Related Amyloidosis
Title: First Device Approved for Dialysis-Related AmyloidosisCategory: Health NewsCreated: 3/6/2015 12:00:00 AMLast Editorial Review: 3/9/2015 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - March 9, 2015 Category: Rheumatology Source Type: news

FDA authorizes use of first device to treat patients with dialysis-related amyloidosis
The U.S. Food and Drug Administration today authorized use of Lixelle Beta 2-microglobulin Apheresis Column, the first device to treat dialysis-related amyloidosis (DRA). (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 6, 2015 Category: American Health Source Type: news

Amyloid formation may link Alzheimer disease and type 2 diabetes
The pathological process amyloidosis, in which misfolded proteins (amyloids) form insoluble fibril deposits, occurs in many diseases, including Alzheimer disease (AD) and type 2 diabetes mellitus (T2D). However, little is known about whether different forms of amyloid proteins interact or how amyloid formation begins in vivo. A new study has found evidence that amyloid from the brain can stimulate the growth of fibrils in the murine pancreas and pancreatic-related amyloid can be found along with brain-related amyloid in human brain senile plaques. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 17, 2015 Category: Science Source Type: news

Amyloid formation may link Alzheimer disease and type 2 diabetes
(Elsevier Health Sciences) The pathological process amyloidosis, in which misfolded proteins (amyloids) form insoluble fibril deposits, occurs in many diseases, including Alzheimer disease and type 2 diabetes. A study published in The American Journal of Pathology has found evidence that amyloid from the brain can stimulate the growth of fibrils in the murine pancreas and pancreatic-related amyloid can be found along with brain-related amyloid in human brain senile plaques. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 17, 2015 Category: Global & Universal Source Type: news